(SGRY) Surgery Partners - NASDAQ
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.793m USD | Total Return: -33.7% in 12m
Avg Turnover: 16.7M
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 2
Warnings
Extended 1w
Tailwinds
Confidence
Surgery Partners, Inc. (SGRY) operates a diversified network of surgical facilities across the United States, primarily focusing on non-emergency procedures. Its portfolio includes ambulatory surgery centers (ASCs) and surgical hospitals specializing in high-demand disciplines such as orthopedics, ophthalmology, and gastroenterology. The company supplements its core surgical operations with ancillary services, including diagnostic testing, anesthesia, and multi-specialty physician practices.
The business model leverages the structural shift of surgical procedures from high-cost inpatient hospital settings to lower-cost outpatient facilities. This trend is driven by advancements in minimally invasive technology and payer preferences for cost-effective care delivery. As a provider in the Health Care Facilities sub-industry, SGRY relies on a mix of physician partnerships and organic case volume growth to drive revenue.
Investors can further evaluate the companys valuation metrics and historical performance by reviewing the data on ValueRay. Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners continues to expand its footprint through the acquisition and development of single- and multi-specialty centers.
- Orthopedic and cardiology case migration to outpatient centers drives higher net revenue
- Strategic health system partnerships accelerate facility acquisition and market share growth
- High interest rates increase debt service costs for leveraged facility expansion
- Payer shift toward value-based care models improves facility utilization and margins
- Labor inflation for specialized nursing staff pressures operating margins and EBITDA growth
| Net Income: -76.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.41 > 1.0 |
| NWC/Revenue: 14.98% < 20% (prev 15.92%; Δ -0.94% < -1%) |
| CFO/TA 0.03 > 3% & CFO 280.0m > Net Income -76.1m |
| Net Debt (4.16b) to EBITDA (973.4m): 4.27 < 3 |
| Current Ratio: 1.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.4m) vs 12m ago 1.39% < -2% |
| Gross Margin: 21.68% > 18% (prev 23.71%; Δ -2.03% > 0.5%) |
| Asset Turnover: 41.82% > 50% (prev 39.91%; Δ 1.90% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBIT TTM 795.2m / Interest Expense TTM 666.1m) |
| A: 0.06 (Total Current Assets 1.08b - Total Current Liabilities 581.7m) / Total Assets 8.04b |
| B: -0.11 (Retained Earnings -851.1m / Total Assets 8.04b) |
| C: 0.10 (EBIT TTM 795.2m / Avg Total Assets 8.00b) |
| D: 0.37 (Book Value of Equity 1.69b / Total Liabilities 4.56b) |
| Altman-Z'' = 1.12 = BB |
| DSRI: 1.00 (Receivables 603.4m/570.6m, Revenue 3.34b/3.17b) |
| GMI: 1.09 (GM 23.71% / 21.68%) |
| AQI: 1.01 (AQ_t 0.69 / AQ_t-1 0.69) |
| SGI: 1.05 (Revenue 3.34b / 3.17b) |
| TATA: -0.04 (NI -76.1m - CFO 280.0m) / TA 8.04b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of June 13, 2026, the stock is trading at USD 14.94 with a total of 1,346,254 shares traded.
Over the past week, the price has changed by +11.67%,
over one month by +9.59%,
over three months by +20.17% and
over the past year by -33.72%.
Surgery Partners has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy SGRY.
- StrongBuy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18 | 20.1% |
P/E Forward = 19.8413
P/S = 0.5363
P/B = 1.0599
P/EG = 1.66
Revenue TTM = 3.34b USD
EBIT TTM = 795.2m USD
EBITDA TTM = 973.4m USD
Long Term Debt = 3.61b USD (from longTermDebt, last quarter)
Short Term Debt = 142.6m USD (from shortTermDebt, last quarter)
Debt = 4.34b USD (from shortLongTermDebtTotal, last quarter) + Leases 314.1m
Net Debt = 4.16b USD (calculated: Debt 4.34b - CCE 182.3m)
Enterprise Value = 5.95b USD (1.79b + Debt 4.34b - CCE 182.3m)
Interest Coverage Ratio = 1.19 (Ebit TTM 795.2m / Interest Expense TTM 666.1m)
EV/FCF = 28.62x (Enterprise Value 5.95b / FCF TTM 208.0m)
FCF Yield = 3.49% (FCF TTM 208.0m / Enterprise Value 5.95b)
FCF Margin = 6.22% (FCF TTM 208.0m / Revenue TTM 3.34b)
Net Margin = -2.28% (Net Income TTM -76.1m / Revenue TTM 3.34b)
Gross Margin = 21.68% ((Revenue TTM 3.34b - Cost of Revenue TTM 2.62b) / Revenue TTM)
Gross Margin QoQ = 15.01% (prev 23.98%)
Tobins Q-Ratio = 0.74 (Enterprise Value 5.95b / Total Assets 8.04b)
Interest Expense / Debt = 15.34% (Interest Expense 666.1m / Debt 4.34b)
Taxrate = 14.75% (16.8m / 113.9m)
NOPAT = 677.9m (EBIT 795.2m * (1 - 14.75%))
Current Ratio = 1.86 (Total Current Assets 1.08b / Total Current Liabilities 581.7m)
Debt / Equity = 2.57 (Debt 4.34b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 4.27 (Net Debt 4.16b / EBITDA 973.4m)
Debt / FCF = 20.00 (Net Debt 4.16b / FCF TTM 208.0m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.95% (Net Income -76.1m / Total Assets 8.04b)
RoE = -4.43% (Net Income TTM -76.1m / Total Stockholder Equity 1.72b)
RoCE = 14.91% (EBIT 795.2m / Capital Employed (Equity 1.72b + L.T.Debt 3.61b))
RoIC = 9.12% (NOPAT 677.9m / Invested Capital 7.44b)
WACC = 11.71% (E(1.79b)/V(6.14b) * Re(8.41%) + D(4.34b)/V(6.14b) * Rd(15.34%) * (1-Tc(0.15)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 0.91%
[DCF] Terminal Value 67.89% ; FCFF base≈194.1m ; Y1≈222.5m ; Y5≈327.5m
[DCF] Fair Price = N/A (negative equity: EV 3.08b - Net Debt 4.16b = -1.08b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.62 | Revenue CAGR: 9.69% | SUE: 0.95 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=N/A | Revisions=+27% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.14 | Chg30d=+98.69% | Revisions=+50% | Analysts=10
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=+129.91% | Revisions=+54% | GrowthEPS=-3.2% | GrowthRev=+3.0%
EPS next Year (2027-12-31): EPS=0.64 | Chg30d=+66.60% | Revisions=+67% | GrowthEPS=+41.0% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +67%